Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026

Twelve new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended twelve medicines for approval at its July 2026 meeting.The committee…, CHMP statistics Key figures from the July 2026 CHMP meeting are represented in the graphic below. © European Medicines Agency , CHMP statistics:…, Positive recommendations on new medicines, Evlarco International non-proprietary name (INN) obicetrapib / ezetimibe Marketing authorisation applicant A. Menarini International Licensing S.A.…, Icotyde INN icotrokinra hydrochloride Marketing authorisation applicant Janssen-Cilag International N.V. Therapeutic indication Treatment of moderate to…, Lynavoy INN linerixibat Marketing authorisation applicant Glaxosmithkline Trading Services Limited Therapeutic indication Treatment of cholestatic pruritus in…, Lyrokaul INN lerodalcibep Marketing authorisation applicant LIB Therapeutics B.V. Therapeutic indication Treatment of adults with primary…, Nezglyal INN leriglitazone Marketing authorisation applicant Minoryx Therapeutics S.L. Therapeutic indication Treatment of cerebral…, Susvimo INN ranibizumab Marketing authorisation applicant Roche Registration GmbH Therapeutic indicatio